Literature DB >> 35223872

Incidence of Pseudophakic Cystoid Macular Oedema Post-Cataract Surgery in Illawarra Shoalhaven Local Health District, Australia.

Ishith Seth1, Gabriella Bulloch2, Alvin Tan3, Erin Thornell4, Smita Agarwal4.   

Abstract

BACKGROUND: Post-operatively, cataract surgery is associated with pseudophakic cystoid macular oedema (PCMO) causing vision disturbances. The presence of comorbidities may increase the incidence of PCMO post-cataract surgery.
OBJECTIVE: This observational study aimed to assess the incidence of PCMO in Australia (Illawarra region) and identify risk factors for developing PCMO.
METHODS: Retrospective analysis was performed on data from patients who underwent uncomplicated phacoemulsification and intraocular lens implantation between 1st March and June 30, 2016. Demographics, comorbidities, central subfield thickness (CST), visual acuity, and intraocular pressure (IOP) were collected preoperatively, day 1, and weeks 2, 4, and 6 post-operatively. Statistical analysis was performed using SPSS v.27.0 and GraphPad Prism v.9.0. The median and 95% confidence intervals were used to describe data. Logistic regression and χ2 tests were used to describe the associations. We followed the Declaration of Helsinki guidelines.
RESULTS: Fifty right and 35 left cataract eyes were operated on (58.8% were females; average age 72.8 ± 8.146 years). Total PCMO incidence was 10.6%, and true PCMO incidence (removing PCMO risk factors) was 4.2% at week 6 post-operatively. CST was slightly increased between pre- and post-cataract surgery at week 4 (p = 0.002) and week 6 (p < 0.0001; median = 259 μm, 264 μm, and 263 μm, respectively). IOP was found to be decreased (p < 0.0001) compared to day 1 (median = 17 mm Hg) and week 6 (median = 13 mm Hg). The probability of developing PCMO (odds ratio [OR] = 3) and vitreomacular traction (OR = 2.9) was higher in diabetic patients compared to non-diabetic patients and in patients >65 years old (OR = 1.5).
CONCLUSION: The true incidence of PCMO was found to be the greatest at 2-4 weeks post-operatively. Patients with diabetes or advanced age (>65 years) are at an elevated risk of developing PCMO after cataract surgery. The treatment regimens for the comorbid populations, especially diabetic patients, remain limited, and future efforts should target pharmaceutical management for these groups.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Cataract; Comorbidities; Pseudophakic cystoid macular oedema

Year:  2022        PMID: 35223872      PMCID: PMC8832185          DOI: 10.1159/000521053

Source DB:  PubMed          Journal:  Biomed Hub        ISSN: 2296-6870


  48 in total

1.  Effect of preoperative topical nepafenac 0.1% on inflammatory response after uncomplicated cataract surgery in healthy subjects.

Authors:  Carlo Cagini; Alessio Cerquaglia; Adriana Pellegrino; Alessia Iannone; Marco Lupidi; Tito Fiore
Journal:  Acta Ophthalmol       Date:  2020-06-18       Impact factor: 3.761

2.  Incidence of acute postoperative cystoid macular edema in clinical practice.

Authors:  Mark Packer; Jennifer Lowe; Howard Fine
Journal:  J Cataract Refract Surg       Date:  2012-10-16       Impact factor: 3.351

3.  Risk factors for and diagnosis of pseudophakic cystoid macular edema after cataract surgery in diabetic patients.

Authors:  Jin Yang; Lei Cai; Zhongcui Sun; Hongfei Ye; Qi Fan; Keke Zhang; Wenyi Lu; Yi Lu
Journal:  J Cataract Refract Surg       Date:  2017-02       Impact factor: 3.351

4.  Macular thickness measured by optical coherence tomography in a healthy population before and after uncomplicated cataract phacoemulsification surgery.

Authors:  Carlo Cagini; Tito Fiore; Barbara Iaccheri; Francesco Piccinelli; Maria Antonietta Ricci; Daniela Fruttini
Journal:  Curr Eye Res       Date:  2009-12       Impact factor: 2.424

5.  Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema.

Authors:  Jost B Jonas; Ingrid Kreissig; Robert F Degenring
Journal:  Am J Ophthalmol       Date:  2003-08       Impact factor: 5.258

6.  Spontaneous resolution of vitreomacular traction: a case series.

Authors:  Ozlem Barut Selver; Melih Parlak; Zeynep Ozbek Soylemezoglu; Ali Osman Saatci
Journal:  Clin Exp Optom       Date:  2013-01-24       Impact factor: 2.742

7.  Evaluation of costs for cystoid macular edema among patients after cataract surgery.

Authors:  Jordana K Schmier; Michael T Halpern; David W Covert; G Philip Matthews
Journal:  Retina       Date:  2007-06       Impact factor: 4.256

8.  European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1.

Authors:  Laura H P Wielders; Jan S A G Schouten; Bjorn Winkens; Frank J H M van den Biggelaar; Claudette A Veldhuizen; Oliver Findl; Joaquim C N Murta; Willem R O Goslings; Marie-José Tassignon; Maurits V Joosse; Ype P Henry; Alexander H F Rulo; José L Güell; Michael Amon; Thomas Kohnen; Rudy M M A Nuijts
Journal:  J Cataract Refract Surg       Date:  2018-04       Impact factor: 3.351

9.  Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema.

Authors:  Marta S Figueroa; Inés Contreras; Susana Noval
Journal:  Retina       Date:  2008-03       Impact factor: 4.256

10.  The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery-a Scottish Ophthalmological Surveillance Unit study.

Authors:  Ore-Oluwa Erikitola; Thomas Siempis; Barny Foot; David Lockington
Journal:  Eye (Lond)       Date:  2020-05-06       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.